A Study to Assess the Clinical Efficacy of IONIS-PKK-LRx in Participants With Hereditary Angioedema

Open to people ages 18 years and up

• Documented diagnosis of HAE-1/HAE-2 (for inclusion in Part A) or HAE-nC1-INH (for inclusion in Part B)
• Participants must experience a minimum of 2 HAE attacks (assessed by the Angioedema Activity Score [AAS] and confirmed by the investigator) during the screening period
• Access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks

• Anticipated use of short-term prophylaxis for angioedema attacks for a pre-planned procedure during the screening or study periods
• Concurrent diagnosis of any other type of recurrent angioedema, including acquired or idiopathic angioedema
• Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C, or chronic hepatitis B
• Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated
• Treatment with another investigational drug or biological agent within 1 month or 5 half-lives, whichever is longer, of screening
• Exposure to any of the following medications:
• Angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption (such as oral contraceptive or hormonal replacement therapy) within 4 weeks prior to screening
• Chronic prophylaxis with lanadelumab within 10 weeks prior to screening
• Oligonucleotides (including small interfering ribonucleic acid [RNA]) within 4 months of screening (if single dose received) or within 12 months of screening (if multiple doses received)